SE0500056D0 - Therapeutic agents 4 - Google Patents

Therapeutic agents 4

Info

Publication number
SE0500056D0
SE0500056D0 SE0500056A SE0500056A SE0500056D0 SE 0500056 D0 SE0500056 D0 SE 0500056D0 SE 0500056 A SE0500056 A SE 0500056A SE 0500056 A SE0500056 A SE 0500056A SE 0500056 D0 SE0500056 D0 SE 0500056D0
Authority
SE
Sweden
Prior art keywords
compounds
therapeutic agents
nr1h2
nr1h3
dyslipidemias
Prior art date
Application number
SE0500056A
Other languages
English (en)
Inventor
Marianne Swanson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0500056A priority Critical patent/SE0500056D0/sv
Publication of SE0500056D0 publication Critical patent/SE0500056D0/sv
Priority to JP2007550338A priority patent/JP2008526843A/ja
Priority to US11/813,458 priority patent/US20080319017A2/en
Priority to EP06700066A priority patent/EP1838684A1/en
Priority to PCT/SE2006/000028 priority patent/WO2006073365A1/en
Priority to CNA2006800076606A priority patent/CN101137629A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
SE0500056A 2005-01-10 2005-01-10 Therapeutic agents 4 SE0500056D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0500056A SE0500056D0 (sv) 2005-01-10 2005-01-10 Therapeutic agents 4
JP2007550338A JP2008526843A (ja) 2005-01-10 2006-01-09 肝ｘ受容体モジュレーターとしてのイソチアゾール−３（２ｈ）−チオン１，１−ジオキシドの非アニリン誘導体
US11/813,458 US20080319017A2 (en) 2005-01-10 2006-01-09 Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators
EP06700066A EP1838684A1 (en) 2005-01-10 2006-01-09 Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators
PCT/SE2006/000028 WO2006073365A1 (en) 2005-01-10 2006-01-09 Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators
CNA2006800076606A CN101137629A (zh) 2005-01-10 2006-01-09 作为肝x受体调节剂的异噻唑-3(2h)-硫酮1,1-二氧化物的非苯胺衍生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0500056A SE0500056D0 (sv) 2005-01-10 2005-01-10 Therapeutic agents 4

Publications (1)

Publication Number Publication Date
SE0500056D0 true SE0500056D0 (sv) 2005-01-10

Family

ID=34132529

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0500056A SE0500056D0 (sv) 2005-01-10 2005-01-10 Therapeutic agents 4

Country Status (6)

Country Link
US (1) US20080319017A2 (sv)
EP (1) EP1838684A1 (sv)
JP (1) JP2008526843A (sv)
CN (1) CN101137629A (sv)
SE (1) SE0500056D0 (sv)
WO (1) WO2006073365A1 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
ES2765573T3 (es) 2012-08-13 2020-06-09 Univ Rockefeller Tratamiento y diagnóstico de melanoma
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1119548B1 (en) * 1998-10-08 2004-12-08 SmithKline Beecham plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3)
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU6074700A (en) * 1999-07-08 2001-01-30 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
ATE366238T1 (de) * 2000-05-11 2007-07-15 Consejo Superior Investigacion Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
KR100490402B1 (ko) * 2002-04-16 2005-05-17 삼성전자주식회사 유기 감광체용 오버코트 형성용 조성물 및 이로부터형성된 오버코트층을 채용한 유기 감광체

Also Published As

Publication number Publication date
US20080139616A1 (en) 2008-06-12
US20080319017A2 (en) 2008-12-25
CN101137629A (zh) 2008-03-05
JP2008526843A (ja) 2008-07-24
EP1838684A1 (en) 2007-10-03
WO2006073365A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
SE0500055D0 (sv) Therapeutic agents 3
TW200507836A (en) Therapeutic agents
TW200503691A (en) Therapeutic agents
SE0500056D0 (sv) Therapeutic agents 4
SE0500058D0 (sv) Therapeutic agents 5
BRPI0717023B8 (pt) tiazol pirazolopirimidina, seu uso, e composição farmacêutica
ATE455756T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CA2597069A1 (en) Pyridazine derivatives and their use as therapeutic agents
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BRPI0509069B8 (pt) compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos
BRPI0514448A (pt) derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias
ATE479433T1 (de) Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
WO2018071315A3 (en) Piperidine derivatives as liver x receptor beta agonists, compositions, and their use
WO2008132552A3 (en) Omega-3 lipid compounds
BRPI0516811A (pt) compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
SE0500054D0 (sv) Therapeutic agents 2
BRPI0510223A (pt) compostos, composição cosmética, uso cosmético, uso de um composto, composição farmacêutica e processos para a sìntese de compostos
SE0101978D0 (sv) New compounds
MY143584A (en) Non-anilinic derivatives of isothiazol-3(2h)-one 1, 1-dioxides as liver x receptor modulators
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use